EyePoint, Inc. (EYPT)

EyePoint's stock has been influenced by financial performance and clinical trial advancements. In Q1 2026, the company missed EPS and revenue forecasts due to the completion of deferred revenue recognition from a previous YUTIQ product rights licensing agreement. The company announced Q4 and full-year 2025 financial results, with a decrease in net revenue and an increase in operating expenses. EyePoint has maintained investor interest through the continued progression of DURAVYU in late-stage clinical trials for wet AMD and DME. As of March 31, 2026, EyePoint had $223 million in cash, expected to fund operations into Q4 2027. Over the past year, EYPT's stock price has increased significantly, but it has underperformed the S&P 500 in the last three months.

The provided search results do not contain any information indicating demand seasonality for EyePoint, Inc.'s products or services.

EyePoint, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic products for serious eye diseases, operating in the Healthcare sector and Biotechnology/Pharmaceuticals industry. The company focuses on sustained-release treatments using its Durasert E and Verisome technology platforms, with a portfolio including FDA-approved products and investigational therapies such as ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, DURAVYU for wet age-related macular degeneration and diabetic macular edema, and EYP-2301 for vascular stability in retinal diseases.

EyePoint Pharmaceuticals has operational footprints in the United States, China, and the United Kingdom, with the majority of its revenue generated from the U.S. The company is headquartered in Watertown, Massachusetts, United States.

EyePoint, Inc.'s brand reputation within the financial community appears strong, with a consensus rating of "Buy" or "Strong Buy" from analysts. This positive sentiment is driven by the company's focus on innovative therapies, pipeline advancement, and strategic collaborations. There is no specific information available regarding the company's brand reputation among patients or the broader public, nor any events that have negatively affected its reputation in the past year, beyond the financial misses in recent earnings reports.

EyePoint, Inc. stock ownership is a mix of institutional, retail, and individual investors. Major institutional owners include Suvretta Capital Management, Llc, BlackRock, Inc., Federated Hermes, Inc., Franklin Resources Inc, Vanguard Group Inc, Adage Capital Partners Gp, L.l.c. / Adage Capital Management, L.P., Paradigm Biocapital Advisors LP, Janus Henderson Group Plc, Orbimed Advisors Llc, Geode Capital Management, Llc, Cormorant Asset Management LP, and EW Healthcare Partners LP. Approximately 99.41% of the stock is held by institutions, and insiders hold about 10.81%.